Marco Foppoli
Overview
Explore the profile of Marco Foppoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steffanoni S, Calimeri T, Marktel S, Nitti R, Foppoli M, Ferreri A
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672475
Background: Consolidation therapy has improved the outcome of newly diagnosed PCNSL patients. Whole-brain radiotherapy (WBRT) was the first consolidation strategy used and represented the gold standard for many years, but...
2.
Ferreri A, Angelillo P, Erbella F, Cattaneo C, Verga L, Lleshi A, et al.
Blood Adv
. 2022 May;
6(22):5811-5820.
PMID: 35580327
Patients with aggressive B-cell lymphoma and MYC rearrangement at fluorescence in situ hybridization exhibit poor outcome after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). In the last decade, 68 patients with...
3.
Calimeri T, Steffanoni S, Foppoli M, Ponzoni M, Ferreri A
Expert Opin Ther Targets
. 2021 Oct;
25(9):749-760.
PMID: 34606736
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (PCNSL) represents a relevant challenge in onco-hematology. PCNSL has specific molecular profile and biological characteristics that distinguish it from...
4.
Pesenti G, Foppoli M, Manca D
Cancer Chemother Pharmacol
. 2021 Jun;
88(4):595-606.
PMID: 34120234
Purpose: High-dose methotrexate (HDMTX) is administered for the treatment of a variety of malignant tumors. Wide intra- and inter-individual variabilities characterize the pharmacokinetics of MTX, which is mostly excreted renally....
5.
Ferreri A, Calimeri T, Lopedote P, Francaviglia I, Daverio R, Iacona C, et al.
Br J Haematol
. 2021 Feb;
193(3):497-505.
PMID: 33620087
Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of...
6.
Ferreri A, Cattaneo C, Lleshi A, Verga L, Allione B, Facchetti F, et al.
Br J Haematol
. 2020 Oct;
192(1):119-128.
PMID: 33085777
A few prospective trials in HIV-positive patients with Burkitt lymphoma (BL) or high-grade B-cell lymphoma (HGBL) have been reported. Investigated therapies have shown good efficacy but relevant safety problems, with...
7.
Ferreri A, Calimeri T, Ponzoni M, Curnis F, Conte G, Scarano E, et al.
Blood Adv
. 2020 Aug;
4(15):3648-3658.
PMID: 32766857
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment of diffuse large B-cell lymphoma (DLBCL). Primary DLBCL of the central nervous system (CNS) (primary central nervous system lymphoma...
8.
Ferreri A, Sassone M, Angelillo P, Zaja F, Re A, Di Rocco A, et al.
Hematol Oncol
. 2020 May;
38(3):257-265.
PMID: 32356913
We report final results of a phase II trial addressing efficacy and feasibility of lenalidomide maintenance in patients with chemosensitive relapse of diffuse large B-cell lymphoma (DLBCL) not eligible for...
9.
Ferreri A, Calimeri T, Conte G, Cattaneo D, Fallanca F, Ponzoni M, et al.
Blood
. 2019 May;
134(3):252-262.
PMID: 31118164
Patients with primary central nervous system lymphoma (PCNSL) are treated with high-dose methotrexate-based chemotherapy, which requires hospitalization and extensive expertise to manage related toxicity. The use of R-CHOP (rituximab, cyclophosphamide,...
10.
Cavalli G, Foppoli M, Cabrini L, Dinarello C, Tresoldi M, Dagna L
Front Immunol
. 2017 Feb;
8:131.
PMID: 28232838
Support measures currently represent the mainstay of treatment for fulminant myocarditis, while effective and safe anti-inflammatory therapies remain an unmet clinical need. However, clinical and experimental evidence indicates that inhibition...